Review of the safety and efficacy of ustekinumab Academic Article uri icon

Overview

MeSH Major

  • Anti-Infective Agents
  • Escherichia coli
  • Escherichia coli Proteins
  • Membrane Transport Proteins
  • Rifamycins

abstract

  • Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

publication date

  • September 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3002587

Digital Object Identifier (DOI)

  • 10.1177/1756283X10374216

PubMed ID

  • 21180612

Additional Document Info

start page

  • 321

end page

  • 8

volume

  • 3

number

  • 5